The epidemiology of hepatitis C infection in the United States
- PMID: 17653645
- DOI: 10.1007/s00535-007-2064-6
The epidemiology of hepatitis C infection in the United States
Abstract
Background: The prevalence of hepatitis C virus (HCV) infection in the United States has remained constant from 1988 through 2002, although the peak age of infection has increased. While the number of new HCV cases is declining, the rates of HCV-associated morbidity and mortality are increasing. We reviewed the risk factors for HCV infection, the laboratory methods used to diagnose it, the dynamics of disease progression, and the natural history of HCV infection.
Methods: Medline searches were performed using the key word HCV, together with incidence, risk factors, demographics, diagnostic methods, disease progression, natural history, normal alanine aminotransferase (ALT), fibrosis, and hepatocellular carcinoma (HCC).
Results: Three characteristics-abnormal serum ALT, history of injection drug use, and blood transfusion before 1992-identified 85% of HCV-positive individuals 20-59 years old. About 75%-85% of acutely infected individuals progress to chronic infection, with up to 20% developing liver cirrhosis over 20-25 years, putting them at increased risk for end-stage liver disease and/or HCC. HCV-associated cirrhosis is the leading cause of liver transplantation in the United States. Rates of infection are higher in non-Hispanic blacks than in non-Hispanic whites and Mexican Americans and higher in men than in women. In the United States, over 70% of HCV-infected individuals are infected with genotype 1.
Conclusions: HCV infection is more prevalent than human immunodeficiency virus or hepatitis B virus infection and is particularly common among certain demographic groups. Individual rates of fibrosis progression vary, but identification of host and viral characteristics associated with disease progression may reveal the mechanisms of HCV-associated hepatic fibrosis/cirrhosis.
Similar articles
-
Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.J Epidemiol Biostat. 2001;6(3):243-65; discussion 279-85. J Epidemiol Biostat. 2001. PMID: 11437088
-
Natural history of hepatitis C.J Hepatol. 2014 Nov;61(1 Suppl):S58-68. doi: 10.1016/j.jhep.2014.07.012. Epub 2014 Nov 3. J Hepatol. 2014. PMID: 25443346 Review.
-
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.Minerva Gastroenterol Dietol. 2005 Mar;51(1):31-46. Minerva Gastroenterol Dietol. 2005. PMID: 15756144 English, Italian.
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.Lancet. 1997 Mar 22;349(9055):825-32. doi: 10.1016/s0140-6736(96)07642-8. Lancet. 1997. PMID: 9121257
-
Natural history of hepatitis C.J Hepatol. 1999;31 Suppl 1:17-24. doi: 10.1016/s0168-8278(99)80369-9. J Hepatol. 1999. PMID: 10622555 Review.
Cited by
-
Management of rheumatic disease with comorbid HBV or HCV infection.Nat Rev Rheumatol. 2012 May 8;8(6):348-57. doi: 10.1038/nrrheum.2012.63. Nat Rev Rheumatol. 2012. PMID: 22565315 Review.
-
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.Drugs. 2010;70(2):147-65. doi: 10.2165/11531990-000000000-00000. Drugs. 2010. PMID: 20108989 Review.
-
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol. 2009 Mar 20;27(9):1485-91. doi: 10.1200/JCO.2008.20.7753. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224838 Free PMC article.
-
Evaluation of operational chronic infection endpoints for HCV vaccine trials.Contemp Clin Trials. 2008 Sep;29(5):671-8. doi: 10.1016/j.cct.2008.03.006. Epub 2008 Apr 9. Contemp Clin Trials. 2008. PMID: 18511350 Free PMC article.
-
JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma.Mol Cancer. 2009 Aug 17;8:64. doi: 10.1186/1476-4598-8-64. Mol Cancer. 2009. PMID: 19686584 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical